StemCell Therapy

Plant Biotechnology Services Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026)

A comprehensive research study on the Plant Biotechnology Services Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario. The changes in the market conditions are drastic. The swiftly changing market scenario and initial and future assessment of the impact on Plant Biotechnology Services market is covered in the report.The Plant Biotechnology Services Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Plant Biotechnology Services Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Plant Biotechnology Services industry.

The Global Plant Biotechnology Services Market poised to grow from US$ XX million in 2020 to US$ XX million by 2026 at a compound annual growth rate (CAGR) of XX% during the projection period of 2020-2026.

An Outline of the Major Key Players covered in this Report:

Thermo Fisher Scientific Inc., Agilent Technologies, GenScript Biotech Corporation, Eurofins Scientific SE

Get Free LatestPDF Template of this Report(Including Covid-19 impact analysis on overall industry Forecast, Size, Share, CAGR and more.)@ https://www.marketreportexpert.com/report/Plant_Biotechnology_Services/13966/sample

Note: We can also provide market report in German/French Language.

The report puts together a succinct analysis of the growth drivers influencing the current business scenario across various regions and countries. Substantial information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present a collaborative prediction. Additionally, this report encompasses a precise competitive analysis of major market players, innovative companies, and their strategies during the projection timeline.

The latest report on the Plant Biotechnology Services Market consists of an analysis of this industry and its type, application, and other segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period of 2020-2026.

Majortype, primarily split into

Genomics ServicesAnalytical ChemistryCellular ImagingForage AnalysisTransformation Services

Major applications/end users, including

Research InstitutesPharmaceuticals CompaniesBiotechnology Companies

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

Feel Free! Ask Our Industry Expert For Discount on this Report(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends. Also we are offering 20% discount.): https://www.marketreportexpert.com/report/Plant_Biotechnology_Services/13966/inquiry

The research offers an analysis of the geographical landscape of the Plant Biotechnology Services Market, which is divided into regions such as North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The segment includes data about several parameters related to the regional contribution such as market share, application share, type share, key companies in respective regions, market share of key companies in regional market, growth rate and revenue of the regional market, sales, production, and consumption of the respective Plant Biotechnology Services market.

Major Highlights of TOC Covers:

Plant Biotechnology Services Market 2020, Plant Biotechnology Services Market size, Plant Biotechnology Services Market share, Plant Biotechnology Services Market analysis, Plant Biotechnology Services Market forecast, Plant Biotechnology Services Market trends, Plant Biotechnology Services Market Research report, Plant Biotechnology Services application, Plant Biotechnology Services Trends, Plant Biotechnology Services Market growing CAGR, Plant Biotechnology Services Market Competitive Landscape, Plant Biotechnology Services Market Growth

Information related to the growth rate, revenue, sales, production, consumption, during the forecast period is included in the report. The Plant Biotechnology Services Market report claims that the industry is projected to generate significant revenue and sales during the forecast period. The report consists of information related to the market dynamics such as challenges involved in this vertical, growth opportunities, and driving factors affecting the market.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email inquiry@marketreportexpert.comWeb:-https://www.marketreportexpert.com

Read more:
Plant Biotechnology Services Market Increasing Demand with Leading Player, Comprehensive Analysis 2026| Thermo Fisher Scientific Inc., Agilent...

A rating of 82 puts Denali Therapeutics Inc (DNLI) near the top of the Biotechnology industry according to InvestorsObserver. Denali Therapeutics Inc's score of 82 means it scores higher than 82% of stocks in the industry. Denali Therapeutics Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 25 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Denali Therapeutics Inc (DNLI) stock is trading at $38.82 as of 2:13 PM on Wednesday, Oct 7, a rise of $1.37, or 3.66% from the previous closing price of $37.45. The stock has traded between $37.75 and $39.54 so far today. Volume today is 434,019 compared to average volume of 574,304.

Click Here to get the full Stock Score Report on Denali Therapeutics Inc (DNLI) Stock.

See the article here:
Is Denali Therapeutics Inc (DNLI) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 67 rating InvestorsObserver gives to Blueprint Medicines Corp (BPMC) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, BPMCs 67 overall rating means the stock scores better than 67 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Blueprint Medicines Corp (BPMC) stock is trading at $99.43 as of 3:25 PM on Wednesday, Oct 7, a gain of $2.88, or 2.98% from the previous closing price of $96.55. The stock has traded between $97.13 and $100.52 so far today. Volume today is 381,700 compared to average volume of 494,247.

Click Here to get the full Stock Score Report on Blueprint Medicines Corp (BPMC) Stock.

View original post here:
Is Blueprint Medicines Corp (BPMC) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

A rating of 3 puts Aptorum Group Ltd (APM) near the bottom of the Biotechnology industry according to InvestorsObserver. Aptorum Group Ltd's score of 3 means it scores higher than 3% of stocks in the industry. Aptorum Group Ltd also received an overall rating of 8, putting it above 8% of all stocks. Biotechnology is ranked 25 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aptorum Group Ltd (APM) stock is trading at $2.79 as of 1:12 PM on Wednesday, Oct 7, an increase of $0.10, or 3.72% from the previous closing price of $2.69. The stock has traded between $2.70 and $2.99 so far today. Volume today is 2,313,374 compared to average volume of 2,976,804.

Click Here to get the full Stock Score Report on Aptorum Group Ltd (APM) Stock.

Read the original:
Is Aptorum Group Ltd (APM) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

A rating of 54 puts Wave Life Sciences Ltd (WVE) near the middle of the Biotechnology industry according to InvestorsObserver. Wave Life Sciences Ltd's score of 54 means it scores higher than 54% of stocks in the industry. Wave Life Sciences Ltd also received an overall rating of 51, putting it above 51% of all stocks. Biotechnology is ranked 22 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Wave Life Sciences Ltd (WVE) stock is trading at $8.96 as of 11:28 AM on Tuesday, Oct 6, a gain of $0.45, or 5.29% from the previous closing price of $8.51. The stock has traded between $8.66 and $9.14 so far today. Volume today is below average. So far 748,888 shares have traded compared to average volume of 1,771,971 shares.

Click Here to get the full Stock Score Report on Wave Life Sciences Ltd (WVE) Stock.

Read more from the original source:
Where Does Wave Life Sciences Ltd (WVE) Stock Fall in the Biotechnology Field? - InvestorsObserver

The 48 rating InvestorsObserver gives to LogicBio Therapeutics Inc (LOGC) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 51 percent of stocks in the Biotechnology industry, LOGCs 48 overall rating means the stock scores better than 48 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 48 would rank higher than 48 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

LogicBio Therapeutics Inc (LOGC) stock is trading at $7.64 as of 11:48 AM on Wednesday, Oct 7, a gain of $0.81, or 11.86% from the previous closing price of $6.83. The stock has traded between $6.89 and $7.92 so far today. Volume today is low. So far 186,868 shares have traded compared to average volume of 257,546 shares.

Click Here to get the full Stock Score Report on LogicBio Therapeutics Inc (LOGC) Stock.

Go here to read the rest:
Is LogicBio Therapeutics Inc (LOGC) a Winner in the Biotechnology Industry? - InvestorsObserver

Newswise October 6, 2020 Accelerated crop improvement is needed to meet both global population growth and climate change generated stresses on crops. TheCrop Biotechnology, physiology and translational genomics to feed and fuel the worldsymposium at theTranslating Visionary Science to Practice ASA, CSSA, SSSA International Annual Meetingwill address these topics.

The meeting is being held virtually, Nov. 9-13, 2020 and is hosted by the American Society of Agronomy, Crop Science Society of America and Soil Science Society of America. Media are invited; preregistration is required.

The presentations are:

Presentations may be watched asynchronously, and there will be a scheduled Q&A time to speak with presenters during the meeting. Presentations will be available for online viewing for 90 days after the meeting for all registrants. For more information about theTranslating Visionary Science to Practice 2020meeting,visithttps://www.acsmeetings.org/.

Media are invited to attend the conference. Pre-registration by Nov. 2, 2020 is required. Visithttps://www.acsmeetings.org/mediafor registration information.

To speak with one of the scientists, contact Susan V. Fisk, 608-273-8091,sfisk@sciencesocieties.orgto arrange an interview.

Go here to read the rest:
Crop Biotechnology, physiology and translational genomics to feed and fuel the world - Newswise

(September 2020):WMRsLatest Study on Biotechnology Separation Systems Market report 2020-2027 providesan Overview of the current market situation,competitive analysis, product scope, market research, opportunities, driving force, and market risks. The report contains market forecast to 2027 related to market size, Consumption, gross margin, price,revenue, production, CAGR and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.

The Biotechnology Separation Systems market report provides a basic overview of the industry, including definitions, classifications, applications, and chain structures. Biotechnology Separation Systems market analysis is provided to international markets, including development trends, competitive environment analysis, and key regions development status.

Get the FREE Report Sample (Includes- Keyplayers Profiles, Table and Figures, ToC):https://www.worldwidemarketreports.com/sample/393197

The major manufacturers covered in this report: TERUMO, Wego, Fresenius, Grifols, Haemonetics, Macopharma, JMS, Neomedic, STT, AdvaCare

The Impact Analysis of Coivd-19 on Biotechnology Separation Systems industry:

Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global Biotechnology Separation Systems economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get the Free Analysis on Coivd-19with Report, here you can ask for the Structured Report:https://www.worldwidemarketreports.com/covidimpact/393197

Table of Content (TOC) of Biotechnology Separation Systems Market 2020:Chapter 1 Introduction and OverviewChapter 2 Industry Cost Structure and Economic ImpactChapter 3 Rising Trends and New Technologies with Major key playersChapter 4 Global Biotechnology Separation Systems Market Analysis, Trends, Growth FactorChapter 5 Biotechnology Separation Systems Market Application and Business with Potential AnalysisChapter 6 Global Biotechnology Separation Systems Market Segment, Type, ApplicationChapter 7 Global Biotechnology Separation Systems Market Analysis (by Application, Type, End-User)Chapter 8 Major Key Vendors Analysis of Biotechnology Separation Systems MarketChapter 9 Development Trend of AnalysisChapter 10 Covid-19 AnalysisChapter 10 Conclusion

Any quiry or Customization in ToC, place hre:https://www.worldwidemarketreports.com/quiry/393197

Benefits of buying Overbed Table Market Report:

Else, Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: sales@worldwidemarketreports.com

Link:
Biotechnology Separation Systems Market 2020 Industry Development Analysis, Global Trends, Size, Share, Growth Factors, CAGR Status, Industry Insights...

A rating of 84 puts Esperion Therapeutics Inc (ESPR) near the top of the Biotechnology industry according to InvestorsObserver. Esperion Therapeutics Inc's score of 84 means it scores higher than 84% of stocks in the industry. Esperion Therapeutics Inc also received an overall rating of 67, putting it above 67% of all stocks. Biotechnology is ranked 27 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 67 would rank higher than 67 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Esperion Therapeutics Inc (ESPR) stock is trading at $35.73 as of 11:45 AM on Monday, Oct 5, a rise of $1.55, or 4.53% from the previous closing price of $34.18. The stock has traded between $34.56 and $36.18 so far today. Volume today is low. So far 105,952 shares have traded compared to average volume of 508,530 shares.

Click Here to get the full Stock Score Report on Esperion Therapeutics Inc (ESPR) Stock.

Continue reading here:
Where Does Esperion Therapeutics Inc (ESPR) Stock Fall in the Biotechnology Field? - InvestorsObserver

Vancouver, British Columbia, Canada - TheNewswire - October 5, 2020 - Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE:APP) , FSE: 2FA, (OTC:FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced that it has signed a Memorandum of Understanding ("MOU") with Purity-IQ Incorporated of Canada ("Purity-IQ") (http://purity-iq.com/) to integrate the Purity-IQ Cannabis Authenticity and Purity Standard (CAPS) and its Fingerprint(TM) technology with the GCAC efficacy platform; with a focus on the Canadian medical cannabis and adult-use markets, which are forecast to grow to CA$4.1 billion in 20211.

Following on from its TraceLocker announcement on September 3rd, GCAC is attracting key players in the Canadian medical cannabis space. The company's MOU with Purity-IQ is a significant endorsement of the GCAC blockchain compliance and medical efficacy data collection platform. The proposed cooperation integrates GCAC's efficacy-data with Purity-IQ's CAPS Fingerprint(TM) service, a unique genetic and chemical profile of cannabis cultivars.

GCAC's blockchain medical efficacy smartphone app immutably links a specific Purity-IQ CAPS Fingerprint(TM) cultivar directly to a consumer's anonymous efficacy attestations. This is set to revolutionize the traceability of cannabis efficacy and bring it more in line with formal medical-trial information that a traditional dispensing pharmacist would be able to reference.

Purity-IQ can uniquely identify a cultivar based on a metabolite profile using Nuclear Magnetic Resonance (NMR) and DNA chip bioinformatics. The intent is for Purity-IQ Fingerprints to be referenced by GCAC's efficacy platform to verify 'batch-to-batch' consistency in medical cannabis efficacy programs.

GCAC's CEO, Brad Moore "I have no doubt that our smartphone efficacy-data platform is an industry leader for cannabis. Bringing the Purity-IQ scientific fingerprinting of cannabis cultivars, to which our consumers will report their efficacy, really builds a picture of what works for a consumer and what doesn't. This is where medical cannabis needs to get to and, we're bringing it there!"

Brad Moore continued, "With our blockchain truths and efficacy data-sets, medical practitioners, pharmacists, cultivators and processors gain efficacy data previously only found in formal drug trials. We change that and bring the wisdom-of-the-crowd to bear for medical cannabis efficacy."

Under the agreement, GCAC contributions regarding efficacy are the intellectual property ("IP") of GCAC. Securing GCAC's IP creates an inherent difficulty in replicating, or directly competing with, GCAC's medical cannabis solutions, and this is what the company believes makes GCAC one of the most exciting efficacy platforms in the cannabis and RegTech space.

1 https://www.yahoo.com/news/which-pot-stocks-will-survive-cannabis-bankruptcy-risk-131732204.html

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world's first end-to-end - from patient to regulator - medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and GCAC smart rewards to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Driven by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more Company information, please visit http://www.cannappscorp.com, or review its profiles on http://www.sedar.com and on the Canadian Securities Exchange's website (www.thecse.com).

Purity-IQ IncorporatedPurity-IQ is a Canadian biotechnology company based in Mississauga, Ontario. It is committed to innovation in research and development and in the commercialization of practical and affordable validated quality assurance standards and tools, designed to further support brand product claims related to identity, authenticity, and purity. Purity-IQ focuses on commodities and inputs for the food, drug, beverage, natural health products and cannabis industries.

To schedule an interview, please contact: For more information, please contact:

Bradley Moore Corporate Communications

Chief Executive Officer Telephone: +1 (800) 409-5679

Email: bmoore@cannappscorp.com Email: info@cannappscorp.com

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

See the original post here:
GCAC Strengthens Its Medical Cannabis Efficacy Platform with Purity-IQ Biotechnology to Address a $4.1 Billion Market Opportunity - TheNewswire.ca

The agricultural biotechnologybusiness is anticipated to augment business germination in the projection period of 2020 to 2027 reckoning to USD 74.55 billion by 2027 expanding at an annual growth of 9.94% in the above-mentioned projection years.

The major players covered in the agricultural biotechnology market report areKWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Download Sample PDF Copy of Reporthttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Inquiry For Customize Report With Discount Athttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

Insights of the Study

Global Agricultural Biotechnology Market Drivers & Restraints :

To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-agricultural-biotechnology-market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:[emailprotected]

See the rest here:
Covid-19 Update:Agricultural Biotechnology Market 2020||To Witness The Highest Growth Globally In Coming Years || MITSUI & CO., LTD., AgPlenus...

The Coalition of Epidemic Preparedness for Innovation (CEPI), a global initiative to develop vaccines against emerging epidemics, has named Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology (DBT), as part of the Global Network of Laboratories for centralized assessment of Covid-19 vaccine candidates that are under development.

The Faridabad-based laboratory, under DBT, is one of the six laboratories that have been recognised by the CEPI. The CEPI network will initially involve six labs - one each in Canada, Britain, Italy, the Netherlands, Bangladesh and India, for the assessment of Covid-19 vaccine development.

Under the CEPI Global network, all the laboratories will use the same reagents and follow a common set of protocols to measure the immune response of multiple vaccine candidates under development and trial.

The Department of Biotechnology, Government of India, is supporting efforts for Covid-19 vaccine development and testing. THSTI runs comparability studies with other laboratories internationally and will form an important part of the global network, said DBT Secretary Renu Swarup.

We are very pleased that the bioassay laboratory at Translational Health Science and Technology Institute, an autonomous institute of Department of Biotechnology, has been identified by CEPI for centralised immunoassay analysis for COVID 19 vaccines under development globally. It is well-positioned to run comparability studies with other laboratories internationally and will form an important part of the global network. This is another excellent example of Ind CEPI and CEPI partnership, Swarup added.

Read the original:
Department of Biotechnology lab to be part of global Covid-19 vaccine assessment project - ETHealthworld.com

Food Biotechnology Market research Report is an inestimable supply of perceptive information for business strategists. This Food Biotechnology Market study provides comprehensive data which enlarge the understanding, scope and application of this report.

A specific study of competitive landscape of the global Food Biotechnology Market has granted, providing insights into the corporate profiles, financial standing, recent developments, mergers and acquisitions, and therefore the SWOT analysis. This analysis report will provides a transparent program to readers concern regarding the overall market situation to further choose on this market projects.

The Food Biotechnology Market report profiles the successive companies, which includes: ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF Plant Science, Bayer CropScience AG, Camson Bio Technologies

Get Sample Copy of this Report @ https://www.reportsintellect.com/sample-request/1314522

This report studies the global Food Biotechnology Market status and forecast, categorizes the global Food Biotechnology Market size (value & volume), revenue (Million USD), product price by manufacturers, type, application, and region. Food Biotechnology Market Report by Material, Application and Geography with Global Forecast to 2025 is an connoisseur and extensive research provide details associated with worlds major provincial economic situations, Concentrating on the principle districts (North America, South America Europe, and Asia-Pacific) and the crucial nations (US, Germany, UK, Japan, South Korea, and China).

Reports Intellect analysts are currently working analyzing and integrating their insights on the effect of COVID-19 across diverse industry verticals. These insights are quite promising for different businesses and industries to cope up with this unprecedented downturn and take effective strategic decisions to thrive and proliferate within competitive business ecosystem.

By Types: Transgenic CropsSynthetic Biology Derived Products

By Applications:AnimalsPlants

Market Segment by Regions, regional analysis coversNorth AmericaEuropeAsia-PacificSouth AmericaMiddle East and Africa

Table of Contents

Global Food Biotechnology Market Size, Status and Forecast 20251 Market Overview2 Manufacturers Profiles3 Global Food Biotechnology Sales, Revenue, Market Share andCompetitionby Manufacturer4 Global Food Biotechnology Market Analysis by Various Regions5 North America Food Biotechnology by Countries6 Europe Food Biotechnology by Countries7 Asia-Pacific Food Biotechnology by Countries8 South America Food Biotechnology by Countries9 Middle East and Africas Food Biotechnology by Countries10 Global Food Biotechnology Market Segment by Types11 Global Food Biotechnology Market Segment by Applications12 Food Biotechnology Market Forecast13 Sales Channel, Distributors, Traders and Dealers14 Research Findings and Conclusion15 Appendix

Get a Good Amount of Discount on this report @ https://www.reportsintellect.com/discount-request/1314522

Overview of the chapters analysing the global Food Biotechnology Market in detail:

Reasons why you should buy this report

About Us:-Reports Intellect is your one-stop solution for everythingrelating market researchand market intelligence.

Our team works hard to fetchthe best authentic research reports backed with impeccable data figures that guarantee outstanding resultsanytimefor you.

So, whetheritsthe most recentreport from the researchers or a custom requirement, our team is hereto helpyou within absolute bestmanner.

Contact Us:

[emailprotected]PH + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Read more here:
Food Biotechnology Market Laminar Growth to be witnessed by 2025 & Analysis by ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNET trial were published in Clinical Breast Cancer. The manuscript appears in the October 5, 2020 online issue accessible at https://www.clinical-breast-cancer.com/article/S1526-8209(20)30258-5/fulltext.

ExteNET was a multicenter, randomized, double-blind, Phase III trial of 2,840 HER2-positive eBC patients who received neratinib after neoadjuvant and/or adjuvant therapy with chemotherapy and trastuzumab. Patients were stratified by hormone receptor status and randomly assigned to one year of treatment with either oral neratinib 240 mg/day or placebo. The primary endpoint of the trial was invasive disease-free survival (iDFS) with overall survival as a key secondary endpoint. Within the European Union, neratinib is approved in patients with HR+ breast cancer who initiated treatment within one year of completing an adjuvant trastuzumab containing regimen.

The manuscript presents data focusing on HR+ patients who initiated treatment within a year of completing an adjuvant trastuzumab containing treatment (HR+ /< 1 yr) and subgroups of clinical interest including patients who did not achieve a pathological complete response (no pCR) after neoadjuvant treatment and therefore were at a high risk of disease recurrence. (HR+/ <1 yr, no pCR)

In the HR+ /< 1 yr patient population, the absolute 5-year invasive disease-free survival benefit versus placebo was 5.1% (HR=0.58, 95% CI 0.410.82) and absolute 8-year overall survival benefit was 2.1%. (HR=0.79, 95% CI 0.551.13). The 5-year cumulative incidence of CNS metastases was 0.7% in the neratinib arm and 2.1% in the placebo arm.

In the HR+/ <1 yr, no pCR subgroup of patients that were at a high risk of disease recurrence the absolute 5-year iDFS benefit in the neratinib arm versus placebo was 7.4% (HR=0.60; 95% CI 0.331.07) and the 8-year overall survival benefit was 9.1% (HR=0.47; 95% CI 0.230.92).

Most common grade 3 adverse events were diarrhea (39% vs placebo, 1%; without mandatory anti-diarrheal prophylaxis), vomiting (4% vs <1%), and fatigue (2% vs <1%).

Professor Arlene Chan, Vice Chair Breast Cancer Research Centre WA, said, Deciding on which patients benefit most from a given therapy is an important goal for clinicians. This newly published study provides consistent and durable benefits of neratinib in a subset of HER2-positive early stage breast cancer patients who are considered to be at greater risk of relapse: namely patients with HR+ tumors that did not achieve a pCR after neoadjuvant treatment (no pCR). The benefits demonstrated are meaningful in all endpoints evaluated, including iDFS, OS and CNS recurrence, and thus should help guide future clinical decisions.

Hope S. Rugo, MD, Professor of Medicine, University of California San Francisco Comprehensive Cancer Center, said, HER2-positive HR+ patients who do not achieve a pCR are at increased risk of recurrence, even after receiving current standard of care treatment. In a descriptive subset analysis, extended adjuvant therapy with neratinib demonstrated a positive benefit in these patients not only in iDFS, but also in OS. In addition, the trend toward lower CNS involvement is a very important consideration, given the profound impact of CNS metastasis on future prognosis. These data coupled with the recently published data from the CONTROL study, which shows improved tolerability with dose escalation, should allow more patients to benefit from this important therapy.

Alan H. Auerbach, Chief Executive Officer and President of Puma, added, Although there have been many new treatment options for patients with early stage HER2-positive breast cancer, the risk of disease recurrence remains significant and more must be done. These newly published data demonstrate that neratinib provides a clinically meaningful reduction in the risk of recurrence and provides a very important option for these high risk patients.

About HER2-Positive Breast Cancer

Up to 20% of patients with breast cancer tumors over-express the HER2 protein (HER2-positive disease) and in the ExteNET study, 57% of patients were found to have tumors that were hormone-receptor positive. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer recurring, up to 25% of patients treated with trastuzumab experience recurrence within 10 years, the majority of which are metastatic recurrences.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and http://www.NERLYNX.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

See the original post:
Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone...

The National Institutes of Health (NIH) has awarded $1.48 million to the Tuskegee University College of Veterinary Medicine for breast cancer research. Deepa Bedi, is an associate professor in the Department of Biomedical Sciences and is the principal investigator for the four-year program entitled, Evaluation of HSPD1 (Heat Shock Protein, 60) as a theranostic target for breast cancer. Bedi will evaluate the role of the protein in the progression of breast cancer.

I aim to use this protein as a marker of TNBC progression as well as a target to deliver anti-cancer drugs to this highly aggressive and metastatic cancer. This grant will provide the necessary resources to fulfill this hypothesis and be able to contribute to the knowledge and cure of TNBC, particularly in African American women, Bedi said.

We are proud of the contributions that Bedi will make to biomedical research as she translates the discoveries and observations into therapies in her cancer laboratory in the college, said Dr. Ruby Perry, dean of the College of Veterinary Medicine. The data and information gained from this newly funded research study will heighten awareness and enhance the cancer research program here at Tuskegee University.

We are also appreciative to Dr. Shaik Jeelani, vice president for research and dean of the graduate school, for his support of our faculty and their pursuits of research studies that are relevant to animal and human health, Perry said. Biomedical research, in particular breast cancer, is one of our signature research programs here at the university.

Bedis work in cancer research was previously funded by a $441,000 three-year NIH grant in 2016. She coordinates many efforts across campus with Dr. Clayton Yates, director of the Center for Cancer Research at Tuskegee University.

Previously, using phage display technology in Bedis cancer biomarker discovery and therapeutics lab, she discovered heat shock protein 60 to be highly expressed, and to have a higher expression in Blacks with breast cancer as compared to white Americans.

The U.S. National Library of Medicine says breast cancer is one of the most frequently diagnosed cancers and the leading global cause of cancer death in women, accounting for 23% of cancer diagnoses 1.38 million women and 14% of cancer deaths 458,000 women each year. Triple-negative breast cancers occur in 10% to 15% of patients, yet this disease subtype accounts for almost half of all breast cancer deaths and represents a highly aggressive and metastatic phenotype, specifically among Black women.

Read the original here:
NIH awards $1.48 million grant to Tuskegee University for breast cancer research - Alabama NewsCenter

Taking the lead on a five-year, $100 million federal program, Tufts University will head a wide-ranging international development and research effort to head off future pandemics like COVID-19, which has killed more than one million people and devastated economies around the world.

Experts from several Tufts schools and 12 partner institutions will take part in the project, which was announced by the United States Agency for International Development (USAID) on Sept. 30. They will work with high-risk countries to strengthen their capacity to gain and use essential knowledge about how viruses emerge; collaborate with them to identify human behaviors that lead to outbreaks; and help them prepare their public health systems to contain spread during a pandemic.

The project, named Strategies to Prevent Spillover, or STOP Spillover, will target viral zoonotic diseases infections that originate in animals before they spillover into humans, sometimes with terrifying consequences. There are signs that the SARS-CoV-2 coronavirus may have originated in bats, as did the SARS and MERS viruses in the early 2000s. Ebola most likely originated in bats or primates. Scientists believe people first contracted HIV by hunting and eating chimpanzees. An estimated 70 percent of emerging infectious diseases are zoonotic, and outbreaks are getting more frequent.

Over the last five years alone, more pandemics have emerged than in the previous 15 years, said Saul Tzipori, distinguished professor of microbiology and infectious diseases and Agnes Varis University Chair in Science and Society at Cummings School of Veterinary Medicine.

Some parts of the world are more susceptible to spillover, said Tzipori, who will be a lead researcher on the project. Rural areas where people live near wildlife are more likely to see diseases transfer through infected food and shared drinking and bathing water. Farms and markets that keep domestic and wild animals in close proximity heighten the risk of a virus or other pathogen jumping between species, as does hunting bats, monkeys, pangolins, civets, and other game known as bushmeat.

Its the projects focus on what people can do differently in their daily routines to stop infectious diseases that makes program director Deborah Kochevar, a senior fellow at the Fletcher School of Law and Diplomacy, believe it can succeed.

This project builds on the work of USAIDs Emerging Pandemic Threats program to understand dynamic infectious disease interfaces among animals, people, and the environment, said Kochevar, dean emerita and former Henry and Lois Foster Professor at Cummings School of Veterinary Medicine. Tufts veterinary and medical school faculty have contributed extensively to the EPT program over the past ten years. STOP Spillover broadens our interdisciplinary and interprofessional involvement to include veterinary, medical, nutrition, engineering, and global health diplomacy expertise.

With that in mind, the project will work with 10 nations in Africa and Asia to create country-specific plans for sharing knowledge about emerging pathogens, reducing risks, and responding rapidly should outbreaks happen.

One aim is to empower local expertise in those countries and strengthen their capacity to gain critical knowledge about how viruses emerge, and to refine and use that knowledge effectively, efficiently, and sustainably to reduce the risk of zoonotic viral spillover and spread, said Hellen Amuguni, an associate professor at Cummings School.

Infectious disease experts at Cummings School, known internationally for its contributions to the successful campaign to eradicate the livestock disease rinderpest, will play a key role. Cummings School faculty on the EPT program, led by Tzipori and working with the University of Minnesota, supported the establishment of two university networks comprising dozens of institutions in Asia and Africa. These two networks, Africa One Health University Network (AFROHUN) and Southeast Asia One Health University Network (SEAOHUN), educate and train students and graduates in pandemic preparedness. These networks are essential partners and played important roles in securing the current project.

Having the university networks on the ground, helping to lead this effort, understanding the local situation, understanding the issuesthat's really, really important for us, Amuguni said.

In fact, the project will work from the ground up, with the countries themselves helping to decide what gaps need to be filled, be it better health communications or testing technologies. Ideally, the countries will collaborate with each other directly and share expertise.

We want to walk away at the end of five years having helped to build the capacity of these countries to recognize these pathogens, to be able to respond to them, and should they break out, to ameliorate them, said Jeffrey Griffiths, a professor at the School of Medicine who is well versed in human, animal, and environmental epidemiology.

Although Tufts has strong health-science expertise, its constellation of schools offers more than a microbiologists view of infectious diseases, said Caroline Genco, vice provost for research. And that, she suspects, is what made Tufts proposal distinctive. The call is a little different, she said. It has to do with policy, on-the-ground work in the community, and civic engagement. Thats what Tufts is great at. We have diversity in how we look at this.

At the School of Engineering, Associate Professor Daniele Lantagne brings a body of research on water, sanitation, and disease outbreaks in low-income countries. Meanwhile, team members from the Friedman School of Nutrition Science and Policy, the Feinstein International Center, and the Fletcher School of Law and Diplomacy will bring relationships with international public- health programs and experience with complex emergencies.

The Broad Institute, one of the project partners and an expert on viral genomics, will be working with Tufts to adapt its diagnostic tools for use in this project. But STOP Spillover will involve far more than testing wildlife for pathogens. The goal is to look holistically at the entire spillover ecosystem, taking into account the cultural, economic, political, and environmental factors that make viral spillover and spread likely.

One investigative path will be figuring out why people eat certain wild animalsis it culturally important or just whats available or affordable?and then devising ways to change those behaviors.

Many people think that the solution is as simple as shutting down wildlife farms or markets, Amuguni said. But these markets and farms are a source of livelihood for people.

Griffiths agreed. People are engaged in these behaviors because it allows them to survive, he said. What you want to do is figure out how to get around it.

In some cases, the solutions are as much in the realm of economics as in the biological sciences, said Patrick Webb, Alexander MacFarlane Professor at the Friedman School. What foods do people buy? Why do they spend on that instead of something else? And what are the economic incentives that we can put in place to change those decisions?

Governments, for example, could enact policies that make other forms of meat, eggs or other nutrient-rich foods cheaper than bushmeat.

Ecology, too, plays a large role in pandemic risks. Deforestation can force wildlife to move closer to humans, increasing the chances of a disease spillover. At the same time, more frequent droughts in countries such as Uganda have prompted farmers there to cultivate more acreagesometimes encroaching on wildlife habitatsin a bid to salvage some crops should others fail.

Vulnerable farmers often push farther and farther into the forest margins, just to try and have an insurance policy by expanding the land area that they cultivate, Webb said.

Here, the solutions could be technological: Farmers might change that practice if they have access to better seeds, better markets, and better irrigation.

The project will look at how spillover is influenced by pollution, climate changeeven gender. (Hunters are typically men, but women are often responsible for the nutrition and health of a household.)

Tufts scientists have long recognized that human, animal, and environmental health are interconnecteda concept known as One Health. The shocking consequences of the COVID-19 pandemic have driven that message home.

If we disrupt animal life cycles, we may be inviting their pathogens to come on over and join our human families, Kochevar said. Humans need to be thoughtful about the impact they have on other living things. We need to appreciate that our human health depends upon the health of other creatures and the integrity of our shared ecosystems.

Julie Flaherty can be reached at julie.flaherty@tufts.edu. Top photo: Neil Brandvold, Creative Commons license.

Read more:
A Push to Prevent the Next Pandemic - Tufts Now

SACRAMENTO (CBS13) A new partnership is working to save wildlife that has been injured in Californias wildfires.

The Wildlife Disaster Network is a partnership between veterinarians at UC Davis and the California Department of Fish and Wildlife, along with many volunteers. The goal is to send in search and rescue teams to find and treat animals.

So far, they have had their work cut out for them, treating injured bears, mountain lions, coyotes, and more. Many of them are suffering from severe burns and are on long roads to recovery.

With wildlife, you certainly have a few more challenges than you would taking care of your dog or cat. One of them is when they want to take off a bandage theyre pretty much going to take off the bandage. So you have to be creative, Jamie Peyton, with the UC Davis School of Veterinary Medicine, said.

READ:Pets Burned In Camp Fire Healing With Fish Skin Bandages

That creativity involves special bandages made of fish skin that are OK for the animals to chew.

On Monday, crews were able to release a recovered bear back into the wild, which is the goal for all of the animals they work with.

The Wildlife Disaster Network says one of the keys to their process is having the public report injured wildlife to them. They have established a hotline 1-800-WHC-OIL-9 (1-800-942-6459) for first responders, utility workers and the general public to call in for assistance with coordinating care for injured wildlife.

Go here to read the rest:
Wildlife Disaster Network Treats Animals Burned In Wildfires - CBS Sacramento

BETHLEHEM, Pa. (WLVT) - Mans best friend is sniffing out one of Pennsylvanias biggest agricultural threats.

"For us it was literally, can the dogs be trained to find these eggs, can they be trained to find these eggs while ignoring all these other controls," explains Jennifer Essler, PhD, from the University of Pennsylvania's School of Veterinary Medicine, "as you know, these eggs are normally on trees and cars and we had to make sure that the dogs can really hone in on that."

A new program out of The University of Pennsylvanias School of Veterinary Medicine is training dogs to smell out the Spotted Lanternfly. While the human nose cannot detect the invasive pest, a dogs snout doesnt skip a beat.

"Dogs see the world with their nose just like we see the world with our eyes," Essler tells PBS39, "But the really critical thing about dogs is that they communicate with us. So there are tons of animals in the animal kingdom that have as good, or better, olfactory capabilities as dogs but we need to not only train them to find eggs but to tell us that theyve found the eggs! So thats really the critical point and the relationship that dogs have with humans and their willingness to work with us and cooperate with us really makes them special for these types of tasks."

Beyond causing severe damage to trees and heavily affecting quality of life for humans, experts warn the Spotted Lanternfly poses a serious threat to the states agriculture industry. But UPenn researchers have found that dogs are perfectly capable of sniffing out the insects eggs with extreme accuracy. That is, of course, after rigorous training.

"For the dogs we used in the study, we were very lucky. They were already trained to find odors so they knew the game; find this odor and get a reward whether its a toy or food," Essler says, "So for this task, it started with putting the SLF egg in like a tin on the floor and when they showed any interest or sniffed it, we have a clicker that we use to mark that behavior and they get a reward. Just pairing that odor with that game and increasing it in difficulty like adding in other odors that might, in our mind, trip them up or things they need to learn to ignore, ramping up the game closer and closer to what they would need to do in the real world."

VO4: Penn Vets pilot training program comes at the perfect time. Right now is prime egg laying season for the Spotted Lanternfly and experts say early egg-mass detection through canine surveillance might just be the edge needed to fight the spread of the insect in Pennsylvania.

"They basically have a one year lifespan so all these crazy bugs you see, theyll all die by winter. But what they do leave is their eggs. Their eggs do this process that we call overwintering; so, theyll sit on the trees from now until early spring and then thats when the life cycle starts again and youll start to see those tiny bugs," Essler tells PBS39 News Tonight, "and so this is a really critical time because other than humans or other animals moving these eggs, they are stationary and so it's a good time for researchers and those working with this pest to go in and either access the eggs in an area or make sure they dont leave a quarantine zone."

The program is back up and running after coronavirus put it on pause for a few months, so lanternflies watch out.

Read this article:
How Dogs are Being Trained to Help Fight Off Spotted Lanternfly - PBS39.org

Dublin, Oct. 06, 2020 (GLOBE NEWSWIRE) -- The "Pyrethrin Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type, Pest Types, Application" report has been added to ResearchAndMarkets.com's offering.

According to this report the market was valued at US$ 235.35 million in 2019 and is projected to reach US$ 353.53 million by 2027; it is expected to grow at a CAGR of 5.3% from 2020 to 2027.The report highlights key factors driving the market growth and prominent players along with their developments in the market.

Pyrethrin are classified as a class of organic compounds which are obtained from chrysanthemum cinerariifolium that can act as effective insecticides by targeting the nervous system of insects. Pyrethrins are treated as an organic insecticide in combination with piperonyl butoxide or other synthetic adjuvants and is known for its insecticidal and insect repellent characteristics features. They are increasingly being used as an effective alternative of organochlorides and organophosphates and are highly preferred to pyrethroids, a synthetic form of pyrethrin which gets accumulated in the environment.

Pyrethrin is widely used in veterinary medicine for agricultural and domestic purposes. It is used for the treatment of ectoparasites in large and small animals and also in non-mammalian species such as birds, fish, and honeybees. It is used in veterinary medicine in various formulations, including spot-on, sprays, ear tags, soluble powders, and dips. Apart from its usage as veterinary medicine, it is also used in treatment of lices and scabies. Also, permethrin cream, prepared from pyrethrin, is often recommended during pregnancy and lactation. Synthetic pyrethroids have been classified into two types: type I and type II. It is observed that the addition of the alpha-cyano group to the 3-phenoxylbenzyl alcohol group in type II has increased the insecticidal potency. Pyrethrin and piperonyl butoxide are used to make a skin and hair shampoo. It is applied twice to thrice to treat lice. Pyrethrin is also used in body lice medicines such as A-200, Pyrinate, Barc, Lice-Enz, Licetrol, Pronto, Tisit, Tisist blue, and Tripple X. The medical applications of pyrethrin are boosting the demand for pyrethrin all across the globe.

The COVID-19 pandemic has been affecting economies and industries in various countries, including the US, Brazil, Russia, India, Italy, the UK, Iran, and Spain. Chemicals and materials is one the world's major industries suffering serious disruptions in the form of supply chain breaks, event cancellations, and office shutdowns as a result of the lockdowns imposed in various countries to contain the disease spread. China is the global manufacturing hub and the largest raw material supplier for various industries; it is also one of the worst-affected countries by the COVID-19 pandemic. The lockdown of various plants and factories in China is affecting the global supply chains and adversely impacting the manufacturing and sales of various chemical and materials. These factors are likely to restrain the growth of various markets related to the chemicals and materials industry in next few financial quarters.

Botanical Resources Australia Pty Ltd; China Xi'an Nutrendhealth Biotechnology Co, Ltd; Endura; Zhejiang Rayfull Chemicals Co.,Ltd.; Pestech Australia Pty Ltd. Scintex; Sumitomo Chemical Co., Ltd. Horizon Sopyrwa; Kapi Limited; and Zhengzhou Delong Chemical Co., Ltd are among the well-established players in the global pyrethrin market.

Reasons to Buy:

Key Topics Covered:

1. Introduction1.1 Study Scope1.2 Research Report Guidance1.3 Market Segmentation

2. Key Takeaways

3. Research Methodology3.1 Scope of the Study3.2 Research Methodology3.2.1 Data Collection:3.2.2 Hypothesis formulation:3.2.3 Macro-economic factor analysis:3.2.4 Developing base number:3.2.5 Data Triangulation:3.2.6 Country level data:

4. Pyrethrin Market Landscape4.1 Market Overview4.2 PEST Analysis4.2.1 North America4.2.2 Europe4.2.3 APAC4.2.4 MEA4.2.5 SAM4.3 Expert Opinion

5. Pyrethrin Market - Key Market Dynamics5.1 Market Drivers5.1.1 Pyrethrin as an organic insecticide favours market growth5.1.2 Medicinal applications of Pyrethrin5.2 Market Restraints5.2.1 Harmful effects of Pyrethrin5.3 Market Opportunities5.3.1 New pyrethrum industry established in Tasmania, Australia for pyrethrin extract5.4 Future Trends5.4.1 Genetic engineering for natural pyrethrin5.5 Impact Analysis Of Drivers And Restraints

6. Pyrethrin - Global Market Analysis6.1 Pyrethrin Market Overview6.2 Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)6.3 Market Positioning - Key Market Players

7. Pyrethrin Market Analysis - By Type7.1 Overview7.2 Pyrethrin Market, By Type (2019 and 2027)7.3 Pyrethrin I7.3.1 Overview7.3.1.1 Pyrethrin I: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)7.4 Pyrethrin II7.4.1 Overview7.4.1.1 Pyrethrin II: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)

8. Pyrethrin Market Analysis - By Pest Type8.1 Overview8.2 Pyrethrin Market, By Pest Type (2019 and 2027)8.3 Lepidoptera8.3.1 Overview8.3.1.1 Lepidoptera : Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)8.4 Coleoptera8.4.1 Overview8.4.1.1 Coleoptera: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)8.5 Mites8.5.1 Overview8.5.1.1 Mites: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)8.6 Diptera8.6.1 Overview8.6.1.1 Diptera: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)8.7 Others8.7.1 Overview8.7.1.1 Others: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)

9. Pyrethrin Market Analysis - By Application9.1 Overview9.2 Pyrethrin Market, By Application (2019 and 2027)9.3 Agricultural Insecticides9.3.1 Overview9.3.1.1 Agricultural Insecticides: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)9.4 Household Insecticides9.4.1 Overview9.4.1.1 Household Insecticides: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)9.5 Commercial and Industrial9.5.1 Overview9.5.1.1 Commercial and Industrial: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)9.6 Animal Healthcare9.6.1 Overview9.6.1.1 Animal healthcare: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)9.7 Others9.7.1 Overview9.7.1.1 Others: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)

10. Pyrethrin Market - Geographic Analysis10.1 Overview10.2 North America: Pyrethrin Market10.3 Europe: Pyrethrin Market10.4 APAC: Pyrethrin Market10.5 MEA: Pyrethrin Market10.6 SAM: Pyrethrin Market

11. Impact of COVID-19 Pandemic on Global Pyrethrin Market11.1 Overview11.2 North America: Impact Assessment of COVID-19 Pandemic11.3 Europe: Impact Assessment of COVID-19 Pandemic11.4 Asia-Pacific: Impact Assessment of COVID-19 Pandemic11.5 Middle East and Africa: Impact Assessment of COVID-19 Pandemic11.6 South America: Impact Assessment of COVID-19 Pandemic

12. Key Company Profiles12.1 Botanical Resources Australia Pty Ltd.12.1.1 Key Facts12.1.2 Business Description12.1.3 Products and Services12.1.4 Financial Overview12.1.5 SWOT Analysis12.2 China Xi'an Nutrendhealth Biotechnology Co., Ltd.12.2.1 Key Facts12.2.2 Business Description12.2.3 Products and Services12.2.4 Financial Overview12.2.5 SWOT Analysis12.3 Endura12.3.1 Key Facts12.3.2 Business Description12.3.3 Products and Services12.3.4 Financial Overview12.3.5 SWOT Analysis12.4 Zhejiang Rayfull Chemicals Co., Ltd.12.4.1 Key Facts12.4.2 Business Description12.4.3 Products and Services12.4.4 Financial Overview12.4.5 SWOT Analysis12.5 Pestech Australia Pty Ltd.12.5.1 Key Facts12.5.2 Business Description12.5.3 Products and Services12.5.4 Financial Overview12.5.5 SWOT Analysis12.6 Scintex12.6.1 Key Facts12.6.2 Business Description12.6.3 Products and Services12.6.4 Financial Overview12.6.5 SWOT Analysis12.7 Sumitomo Chemical Co., Ltd12.7.1 Key Facts12.7.2 Business Description12.7.3 Products and Services12.7.4 Financial Overview12.7.5 SWOT Analysis12.8 Horizon Sopyrwa12.8.1 Key Facts12.8.2 Business Description12.8.3 Products and Services12.8.4 Financial Overview12.8.5 SWOT Analysis12.9 Kapi Limited12.9.1 Key Facts12.9.2 Business Description12.9.3 Products and Services12.9.4 Financial Overview12.9.5 SWOT Analysis12.10 Zhengzhou Delong Chemical Co., Ltd12.10.1 Key Facts12.10.2 Business Description12.10.3 Products and Services12.10.4 Financial Overview12.10.5 SWOT Analysis

13. Appendix13.1 About the Publisher13.2 Glossary

For more information about this report visit https://www.researchandmarkets.com/r/3lgajp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more:
Worldwide Pyrethrin Industry (2020 to 2027) - by Type, Pest Types, and Application - GlobeNewswire

Pet adoptions have significantly increased during COVID-19

They are cute, they are cuddly, they are a comfort especially in a pandemic, a time many people feel socially isolated and when distractions are welcome.

Updated: 8:31 PM EDT Oct 6, 2020

Hide TranscriptShow Transcript

THAT WAS GOOD NEWS LOOKING -- FOR ANIMALS LOOKING FOR A PERMANENT HOME. >> IT HAS ACTUALLY BEEN REALLY FUN TO HAVE A DOG. WHAT ALSO YOU SUPPOSED TO DO? >> THEY ARE CUTE AND CUDDLY AND THE COMFORT. ESPECIALLY GET A PANDEMIC, A TIME MANY FEEL SOCIALLY ISOLATED AND WHEN DISTRACTIONS ARE WELCOME. >> I GOT JET IN APRIL. I WOULD HAVE BEEN BORED WITHOUT HIM. >> CASINO ALWAYS JOINED BEING A DOGMA WITH TIME ON HER HANDS, COVID PROVIDED THE OPPORTUNITY. >> I GOT LAID OFF. I HAD SO MUCH TIME AND WAS LIKE GOING TO DO IT. >> THE STRASBURGER FAMILY ALSO CONSIDERED A PUPPY BUT TOOK AN UNUSUAL APPROACH IN ADOPTING THEIR POOCH. >> WE KNEW WE WANTED A DOG THAT COULD RUN AROUND ALL DAY AND WHO WAS ALSO BIG ENOUGH NOT TO GET HURT IF THEY ARE TUMBLING AROUND. WITHOUT ADOPTING A DOG FROM A SERVICE TO BE A PERFECT THING. >> DID YOU HAVE ANY HESITATION ABOUT ADOPTING A DOG IN A NEARBY PANDEMIC? >> WE KNEW WE WOULDNT BE COMPLETE WITHOUT A DOG AT HOME. ASK THE PANDEMIC HAS HAD A MAJOR IMPACT ON OUR LIVES, INCLUDING THE ADDITION OF MORE ANIMALS. PET ADOPTIONS ARE UP AROUND THE COUNTRY. 80% OF PETS AND SHELTERS THAT REPORT THEIR DATA WERE ADOPTED, AN INCREASE OVER THE SAME TIME IN 2019. >> THE MS PCA HAS TAKEN IN 21 HUNDRED ANIMALS THE PANDEMIC HIT IN MARCH WHICH THEY SAY IS ABOUT TYPICAL, BUT ADOPTIONS ARE UP ABOUT 20% OVER THE SAME TIME. >> ANY TIME WE HAVE AN ANIMAL THAT IS AVAILABLE, THEYRE GETTING LOTS OF INTEREST AND THEY ARE GOING QUICKLY AND THE LENGTH OF STAY IS DOWN. >> MIKE IS DIRECTOR OF ADOPTION CENTERS AND PROGRAMS. >> WE ARE SEEING A LOT OF PEOPLE MOTIVATED TO TAKE AN ANIMAL ON. PEOPLE ARE WORKING FROM HOME AND THEM THE OPPORTUNITY TO INTRODUCE AN ANIMAL BETTER. WE PIVOTED QUICKLY ON THAT START DOING FACEBOOK LIVE AND BUILT THAT OPPORTUNITY FOR PEOPLE TO CONNECT WITH AN ANIMAL. >> DOGS ARE IN DEMAND BUT SO ARE OTHER FURRY FRIENDS. >> I FEEL LIKE RABBITS DONT GET ENOUGH CREDIT. MOST KNOW THEM FOR BEING IN SMALL CAGES BUT THEY COULD HAVE AS MUCH PERSONALITY AS A DOG OR CAT. THEY CAN BE CALLED AND STRAINED THIS IT WITH YOU ON THE COUCH AND WATCH TV. >> HE SAYS CATS MAKE PERFECT COMPANIONS AND ARE LOOKING FOR FUR-EVER HOMES. >> PEOPLE THINK CATS ARE INDEPENDENT BUT THIS GUYS MORE AFFECTIONATE THAN ANY DOG I HAVE EVER MET. THIS IS THE TYPE OF CAP THAT WANTS TO BE IN A HOME ND NOT A SHELTER. AND YES EVEN CARE THAT WE ARE WEARING MASKS AND LOOK WEIRD RIGHT NOW. >> IN THIS -- AN ASSISTANT PROFESSOR SAYS ANIMALS ARE ABLE TO HELP HUMANS THROUGH STRESSFUL TIMES LIKE THESE NO MATTER THE SIZE, SHAPE OR SPECIES. >> A LOT OF WHAT WE KNOW ABOUT THE SCIENCE OF PET OWNERSHIP IS THAT PEOPLE REALLY TURN TO THEIR PETS AS A SOURCE OF EMOTIONAL SUPPORT. PARTICULARLY WHEN THEY FEEL STRESSED AND AS A NONJUDGMENTAL COMPANION. I THINK THAT DURING THE PANDEMIC, WE ARE NOT ONLY EXPERIENCING A LOT OF STRESS BUT ALSO ISOLATED FROM OTHER PEOPLE WHO MIGHT BE OUR EMOTIONAL WORK AND THATS WHY PETS ARE SO IMPORTANT. >> BROADWAY IS FITTING RIGHT IN AND HAS BECOME MORE THAN A PET. >> HES PART OF THE FAMILY AND HE HAD SO MUCH VALUE >> A MATCH MADE IN HEAVEN, HE IS SUCH A GOOD BOY. >> BROADWAY WAS ADOPTED FROM A NONPROFIT RINSE THE MASK THE TRAINED SERVICE DOGS. HE DIDNT MAKE IT IS A SERVICE DOG BUT NOT BECAUSE HE WAS A BAD STUDENT BECAUSE HE HAD MEDICAL ISSUES. HOUSING INSECURITY IS ONE REASON PEOPLE SURRENDER PETS THEY BELIEVE A TEMPORARY MORATORIUM ON CLOSURES AND EVICTIONS HELP BUT DOES EXPECT A SURGEON INTAKE WHEN THEY EVENTUALLY RESUME.

Pet adoptions have significantly increased during COVID-19

They are cute, they are cuddly, they are a comfort especially in a pandemic, a time many people feel socially isolated and when distractions are welcome.

Updated: 8:31 PM EDT Oct 6, 2020

No matter the size, shape or species, Dr. Megan Mueller, an assistant professor of human animal interaction at Tufts Cummings School of Veterinary Medicine, says animals are able to help humans through stressful times like these.The MSPCA has taken in 2,100 animals since the pandemic hit in March, which they say is about typical. However, adoptions are up about 20% over the same period in 2019. When the Strasburger family decided to adopt a dog, they decided adopting from a service dog organization was the way to go.

No matter the size, shape or species, Dr. Megan Mueller, an assistant professor of human animal interaction at Tufts Cummings School of Veterinary Medicine, says animals are able to help humans through stressful times like these.

The MSPCA has taken in 2,100 animals since the pandemic hit in March, which they say is about typical. However, adoptions are up about 20% over the same period in 2019.

When the Strasburger family decided to adopt a dog, they decided adopting from a service dog organization was the way to go.

Original post:
Pet adoptions have significantly increased during COVID-19 - WCVB Boston